𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The results of imatinib therapy for patients with primary eosinophilic disorders

✍ Scribed by Grzegorz Helbig; Beata Stella-Holowiecka; Sebastian Grosicki; Grazyna Bober; Magorzata Krawczyk; Jerzy Wojnar; Andreas Reiter; Andreas Hochhaus; Jerzy Holowiecki

Book ID
114794015
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
82 KB
Volume
76
Category
Article
ISSN
0902-4441

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Results of imatinib mesylate therapy in
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated

Phase II study of imatinib mesylate as t
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
✍ Arturo Vega-Ruiz; Jorge E. Cortes; Matjaz Sever; Taghi Manshouri; Alfonso QuintΓ‘ πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 375 KB

Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003-2005 in phase II clinical trial with ima